Treatment of recurrent Clostridium difficile-associated disease-Reference-Cited by-同舟云学术

Treatment of recurrent Clostridium difficile-associated disease

Published:2004-11 Issue:1 Volume:1 Page:32-38
ISSN:1743-4378
Container-title:Nature Clinical Practice Gastroenterology & Hepatology
language:en
Short-container-title:Nat Rev Gastroenterol Hepatol

Author:

Surawicz Christina M

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology,Hepatology,General Medicine

Link

http://www.nature.com/articles/ncpgasthep0018.pdf

Reference55 articles.

1. Fekety R (1997) Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. Am J Gastroetnerol 92: 739–750

2. Jarvis B and Shevchuk YM (1997) Recurrent Clostridium difficile diarrhea associated with mitoxantrone and etoposide: a case report and review. Pharmacotherapy 17: 606–611

3. Moskovitz M and Bartlett JG (1981) Recurrent pseudomembranous colitis unassociated with prior antibiotic therapy. Ann Intern Med 141: 663–664

4. Aas J et al. (2003) Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 36: 580–585

5. O'Neill GL et al. (1991) Relapse versus reinfection with Clostridium difficile. Epidemiol Infect 107: 627–635

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transgenic plants expressing a Clostridium difficile spore antigen as an approach to develop low‐cost oral vaccines;Biotechnology Progress;2021-03-16

2. Analysis of C. difficile infection–related outcomes in European participants in the bezlotoxumab MODIFY I and II trials;European Journal of Clinical Microbiology & Infectious Diseases;2020-06-06

3. Exploratory Evaluation of Bezlotoxumab on Outcomes Associated With Clostridioides difficile Infection in MODIFY I/II Participants With Cancer;Open Forum Infectious Diseases;2020-01-31

4. Saccharomyces Cerevisiae Var. Boulardii: Valuable Probiotic Starter for Craft Beer Production;Applied Sciences;2019-08-08

5. Influence of Diagnostic Method on Outcomes in Phase 3 Clinical Trials of Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: A Post Hoc Analysis of MODIFY I/II;Open Forum Infectious Diseases;2019-08-01